PURPOSE: We evaluated the influence of finasteride on prostatic microvessel density to elucidate a mechanism of decreased bleeding in finasteride treated patients with hematuria secondary to benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: A total of 22 patients with clinical BPH and gross hematuria who underwent prostate reductive surgery between 1998 and 2000 were prospectively evaluated. The prostate from 10 finasteride treated and 12 untreated patients was immunohistochemically stained for CD-34. Microvessel density analysis was performed by quantifying positive stained blood vessels located within the stroma of hyperplastic nodules as well as in the suburethral portion of the prostate. RESULTS: Mean microvessel density plus or minus standard deviation in finasteride treated patients was significantly lower in the suburethral portion of the prostate versus untreated controls (14.0 +/- 2.8 versus 20.2 +/- 5.3 vessels per high power field, p <0.05). In the nodular hyperplasia there was no statistically significant difference in the treatment and control groups (mean 17.5 +/- 2.8 and 16.7 +/- 4.6 vessels per high power field, respectively). CONCLUSIONS: Finasteride significantly decreases suburethral prostatic microvessel density in patients with BPH, which may explain its efficacy for decreasing BPH associated bleeding.
PURPOSE: We evaluated the influence of finasteride on prostatic microvessel density to elucidate a mechanism of decreased bleeding in finasteride treated patients with hematuria secondary to benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: A total of 22 patients with clinical BPH and gross hematuria who underwent prostate reductive surgery between 1998 and 2000 were prospectively evaluated. The prostate from 10 finasteride treated and 12 untreated patients was immunohistochemically stained for CD-34. Microvessel density analysis was performed by quantifying positive stained blood vessels located within the stroma of hyperplastic nodules as well as in the suburethral portion of the prostate. RESULTS: Mean microvessel density plus or minus standard deviation in finasteride treated patients was significantly lower in the suburethral portion of the prostate versus untreated controls (14.0 +/- 2.8 versus 20.2 +/- 5.3 vessels per high power field, p <0.05). In the nodular hyperplasia there was no statistically significant difference in the treatment and control groups (mean 17.5 +/- 2.8 and 16.7 +/- 4.6 vessels per high power field, respectively). CONCLUSIONS:Finasteride significantly decreases suburethral prostatic microvessel density in patients with BPH, which may explain its efficacy for decreasing BPH associated bleeding.
Authors: Erin M McAuley; Devkumar Mustafi; Brian W Simons; Rebecca Valek; Marta Zamora; Erica Markiewicz; Sophia Lamperis; Anthony Williams; Brian B Roman; Chad Vezina; Greg Karczmar; Aytekin Oto; Donald J Vander Griend Journal: Am J Pathol Date: 2017-08-18 Impact factor: 4.307
Authors: A Erdem Canda; M Ugur Mungan; Osman Yilmaz; Kutsal Yorukoglu; Emre Tuzel; Ziya Kirkali Journal: Int Urol Nephrol Date: 2006 Impact factor: 2.370
Authors: Hyun Sik Yoon; Min Hyuk Kim; Jae Suk Park; Min Soo Choo; Seong Jin Jeong; Seung-June Oh Journal: Int Neurourol J Date: 2022-06-30 Impact factor: 3.038
Authors: Letteria Minutoli; Mariagrazia Rinaldi; Herbert Marini; Natasha Irrera; Giovanni Crea; Cesare Lorenzini; Domenico Puzzolo; Andrea Valenti; Antonina Pisani; Elena B Adamo; Domenica Altavilla; Francesco Squadrito; Antonio Micali Journal: Int J Mol Sci Date: 2016-08-11 Impact factor: 5.923